{
  "source": "PA-Notification-Afinitor.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1003-14\nProgram Prior Authorization/Notification\nMedication Afinitor® (everolimus)\nP&T Approval Date 12/8/2009, 6/2010, 9/2010, 12/2010, 7/2011, 9/2011, 5/2012, 8/2012,\n7/2013, 8/2014, 8/2015, 7/2016, 7/2017, 5/2018, 5/2019, 5/2020,\n5/2021, 5/2022, 5/2023, 5/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nAfinitor (everolimus) is a kinase inhibitor indicated for the treatment of postmenopausal women\nwith advanced hormone receptor-positive, HER2-negative breast cancer in combination with\nAromasin® (exemestane) after failure of treatment with Femara® (letrozole) or Arimidex®\n(anastrozole); in adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and\nadults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of\ngastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic; adults\nwith advanced renal cell carcinoma (RCC) after failure of treatment with Sutent® (sunitinib) or\nNexavar® (sorafenib); adults with renal angiomyolipoma and tuberous sclerosis complex (TSC),\nnot requiring immediate surgery; treatment of adult and pediatric patients aged 1 year and older\nwith TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic\nintervention but cannot be curatively resected; and for the adjunctive treatment of adult and\npediatric patients aged 2 years and older with TSC-associated partial-onset seizures.1\nAfinitor is not indicated for the treatment of patients with functional carcinoid tumors.\nThe National Cancer Comprehensive Network (NCCN) also recommends use of Afinitor in\ninvasive and inflammatory breast cancer, Waldenström’s macroglobulinemia /\nlymphoplasmacytic lymphoma, neuroendocrine tumors, kidney cancer, soft tissue sarcomas,\nosteosarcomas, gastrointestinal stromal tumors, thymomas and thymic carcinomas, Hodgkin\nlymphoma, follicular, oncocytic, and papillary thyroid carcinomas, subepend",
    "kidney cancer, soft tissue sarcomas,\nosteosarcomas, gastrointestinal stromal tumors, thymomas and thymic carcinomas, Hodgkin\nlymphoma, follicular, oncocytic, and papillary thyroid carcinomas, subependymal giant cell\nastrocytoma (SEGA), meningioma, histiocytic neoplasms, and endometrial carcinoma.2\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n© 2025 UnitedHealthcare Services, Inc.\n1\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Afinitor will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Neuroendocrine Tumors\n1. Initial Authorization\na. Afinitor will be approved based on One of the following criteria:\n(1) Both of the following:\n(a) Diagnosis of one of the following:\ni. Neuroendocrine tumors of gastrointestinal origin\nii. Neuroendocrine tumors of lung origin\niii. Neuroendocrine tumors of thymic origin\n-AND-\n(b) One of the following:\ni. Disease is unresectable\nii. Disease is locally advanced\niii. Disease is metastatic\n-OR-\n(2) Both of the following:\n(a) Diagnosis of neuroendocrine tumors of pancreatic origin\n-AND-\n(b) One of the following:\ni. Used for the management of recurrent, locoregional advanced and/or\nmetastatic disease\nii. Used for management to stabilize glucose levels of locoregional\ninsulinoma\n-OR-\n(3) All of the following:\n© 2025 UnitedHealthcare Services, Inc.\n2\n(a) Diagnosis of well-differentiated, grade 3 neuroendocrine tumor\n-AND-\n(b) One of the following:\ni. Disease is unresectable\nii. Disease is locally advanced\niii",
    "2025 UnitedHealthcare Services, Inc.\n2\n(a) Diagnosis of well-differentiated, grade 3 neuroendocrine tumor\n-AND-\n(b) One of the following:\ni. Disease is unresectable\nii. Disease is locally advanced\niii. Disease is metastatic\n-AND-\n(c) Tumor has favorable biology (e.g., relatively low Ki-67 [<55%], slow\ngrowing, positive SSTR-based PET imaging)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Afinitor will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Afinitor therapy\nAuthorization will be issued for 12 months.\nC. Kidney Cancer\n1. Initial Authorization\na. Afinitor will be approved based on one of the following criteria:\n(1) Both of the following:\n(a) Diagnosis of kidney cancer\n-AND-\n(b) Disease is relapsed or stage IV\n-OR-\n(2) Diagnosis of tuberous sclerosis complex (TSC)-associated renal cell carcinoma\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Afinitor will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Afinitor therapy\n© 2025 UnitedHealthcare Services, Inc.\n3\nAuthorization will be issued for 12 months.\nD. Central Nervous System Cancer\n1. Initial Authorization\na. Afinitor will be approved based on one of the following criteria:\n(1) Both of the following:\n(a) Diagnosis of subependymal giant cell astrocytoma (SEGA)\n-AND-\n(b) Used as adjuvant treatment\n-OR-\n(2) All of the following:\n(a) Diagnosis of meningioma\n-AND-\n(b) Disease is recurrent or progressive\n-AND-\n(c) Surgery and/or radiation is not possible\n-AND-\n(d) One of the following:\ni. Used in combination with bevacizumab (Avastin, Mvasi, etc.)\nii. Used in combination with octreotide acetate LAR\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Afinitor will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Afinitor therapy\nAuthorization will be issued for 12 months.\n",
    "rization\na. Afinitor will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Afinitor therapy\nAuthorization will be issued for 12 months.\nE. Waldenströms Macroglobulinemia or Lymphoplasmacytic Lymphoma\n© 2025 UnitedHealthcare Services, Inc.\n4\n1. Initial Authorization\na. Afinitor will be approved based on both the following criteria:\n(1) Diagnosis of one of the following:\n(a) Waldenströms macroglobulinemia\n(b) Lymphoplasmacytic lymphoma\n-AND-\n(2) One of the following:\n(a) Disease is non-responsive to primary treatment\n(b) Disease is progressive\n(c) Disease has relapsed\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Afinitor will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Afinitor therapy\nAuthorization will be issued for 12 months.\nF. Breast Cancer\n1. Initial Authorization\na. Afinitor will be approved based on all of the following criteria:\n(1) Diagnosis of breast cancer\n-AND-\n(2) One of the following:\n(a) Disease is recurrent\n(b) Disease is metastatic\n-AND-\n(3) One of the following:\n(a) Disease is hormone receptor (HR)-positive [i.e., estrogen-receptor-positive\n(ER+) or progesterone-receptor-positive (PR+)]\n(b) Breast cancer is considered inflammatory\n© 2025 UnitedHealthcare Services, Inc.\n5\n-AND-\n(4) Disease is human epidermal growth factor receptor 2 (HER2)-negative\n-AND-\n(5) One of the following:\n(a) Patient is a postmenopausal woman\n-OR-\n(b) Both of the following:\ni. Patient is a premenopausal woman\nii. Patient is being treated with ovarian ablation/suppression\n-OR-\n(c) Patient is male\n-AND-\n(6) Used in combination with one of the following:\n(a) Exemestane if progressed within 12 months or on a non-steroidal aromatase\ninhibitor [e.g., Arimidex (anastrozole), Femara (letrozole)]\n(b) Fulvestrant\n(c) Tamoxifen\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Afinitor will be approved based on the foll",
    "inhibitor [e.g., Arimidex (anastrozole), Femara (letrozole)]\n(b) Fulvestrant\n(c) Tamoxifen\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Afinitor will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Afinitor therapy\nAuthorization will be issued for 12 months.\nG. Hodgkin Lymphoma\n1. Initial Authorization\na. Afinitor will be approved based on all of the following criteria:\n(1) Diagnosis of classic Hodgkin lymphoma\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n6\n(2) Disease is relapsed or refractory\n-AND-\n(3) Patient is not a candidate for autologous stem cell rescue/high-dose therapy\n(ASCR/HDT)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Afinitor will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Afinitor therapy\nAuthorization will be issued for 12 months.\nH. Soft Tissue Sarcoma\n1. Initial Authorization\na. Afinitor will be approved based on one of the following soft tissue sarcoma subtypes:\n(1) Locally advanced unresectable or metastatic malignant perivascular epithelioid\ncell tumor (PEComa)\n(2) Recurrent angiomyolipoma\n(3) Lymphangioleiomyomatosis\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Afinitor will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Afinitor therapy\nAuthorization will be issued for 12 months.\nI. Thymomas and Thymic Carcinomas\n1. Initial Authorization\na. Afinitor will be approved based on both of the following criteria:\n(1) One of the following:\n(a) Diagnosis of thymic carcinoma\n(b) Diagnosis of thymoma\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n7\n(2) One of the following:\n(a) First-line therapy as a single agent for those who cannot tolerate first-line\ncombination regimens\n(b) Second-line therapy as a single agent\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Afinitor wil",
    "as a single agent for those who cannot tolerate first-line\ncombination regimens\n(b) Second-line therapy as a single agent\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Afinitor will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Afinitor therapy\nAuthorization will be issued for 12 months.\nJ. Thyroid Carcinoma\n1. Initial Authorization\na. Afinitor will be approved based on all of the following criteria:\n(1) Diagnosis of one of the following:\n(a) Follicular carcinoma\n(b) Oncocytic carcinoma\n(c) Papillary carcinoma\n-AND-\n(2) One of the following:\n(a) Unresectable locoreginal recurrent disease\n(b) Persistent disease\n(c) Metastatic disease\n-AND-\n(3) One of the following:\n(a) Patient has symptomatic disease\n(b) Patient has progressive disease\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Afinitor will be approved based on the following criterion:\n© 2025 UnitedHealthcare Services, Inc.\n8\n(1) Patient does not show evidence of progressive disease while on Afinitor therapy\nAuthorization will be issued for 12 months.\nK. Uterine Neoplasms\n1. Initial Authorization\na. Afinitor will be approved based on one of the following criteria:\n(1) Both of the following:\n(a) Diagnosis of endometrial carcinoma\n-AND-\n(b) Used in combination with letrozole\n-OR-\n(2) All of the following:\n(a) Diagnosis of Uterine Sarcoma\n-AND-\n(b) Disease is perivascular epithelioid cell tumor (PEComa)\n-AND-\n(c) Used as second-line or subsequent therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Afinitor will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Afinitor therapy\nAuthorization will be issued for 12 months.\nL. Tuberous Sclerosis Complex associated Partial-onset Seizures\n1. Initial Authorization\na. Afinitor will be approved based on both of the following criteria:\n(1) Diagnosis of tuberous sclerosis complex associat",
    " Sclerosis Complex associated Partial-onset Seizures\n1. Initial Authorization\na. Afinitor will be approved based on both of the following criteria:\n(1) Diagnosis of tuberous sclerosis complex associated partial-onset seizures\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n9\n(2) Used as adjunctive therapy\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Afinitor will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Afinitor therapy\nAuthorization will be issued for 12 months.\nM. Bone Cancer - Osteosarcoma\n1. Initial Authorization\na. Afinitor will be approved based on all of the following criteria:\n(1) Diagnosis of osteosarcoma\n-AND-\n(2) Disease is one of the following:\n(a) Relapsed/Refractory\n(b) Metastatic\n-AND-\n(3) Used as second-line therapy\n-AND-\n(4) Used in combination with Nexavar (sorafenib)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Afinitor will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Afinitor therapy\nAuthorization will be issued for 12 months.\nN. Histiocytic Neoplasms\n1. Initial Authorization\na. Afinitor will be approved based on both of the following criteria:\n© 2025 UnitedHealthcare Services, Inc.\n10\n(1) Diagnosis of one of the following:\n(a) Rosai-Dorfman Disease\n(b) Langerhans Cell Histiocytosis\n(c) Erdheim-Chester Disease\n-AND-\n(2) Presence of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha\n(PIK3CA) mutation\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Afinitor will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Afinitor therapy\nAuthorization will be issued for 12 months.\nO. Gastrointestinal Stromal Tumor (GIST)\n1. Initial Authorization\na. Afinitor will be approved based on all of the following criteria:\n(1) Diagnosis of Gastrointestinal Stromal Tumor (GIST)\n-AND-\n(2) Disea",
    "strointestinal Stromal Tumor (GIST)\n1. Initial Authorization\na. Afinitor will be approved based on all of the following criteria:\n(1) Diagnosis of Gastrointestinal Stromal Tumor (GIST)\n-AND-\n(2) Disease is one of the following:\n(a) Unresectable primary\n(b) Recurrent/metastatic\n(c) Gross residual (R2 resection)\n(d) Tumor rupture\n-AND-\n(3) Disease has progressed after single agent therapy with all of the following:\n(a) Imatinib (Gleevec)\n(b) Qinlock (ripretinib)\n(c) Stivarga (regorafenib)\n(d) Sutent (sunitinib)\n-AND-\n(4) Used in combination with one of the following:\n© 2025 UnitedHealthcare Services, Inc.\n11\n(a) Imatinib (Gleevec)\n(b) Stivarga (regorafenib)\n(c) Sutent (sunitinib)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Afinitor will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Afinitor therapy\nAuthorization will be issued for 12 months.\nP. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category\nof Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Afinitor [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February\n2022.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/profess",
    "initor [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; February\n2022.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/professionals/drug_compendium/content/. April 9, 2025.\nProgram Prior Authorization/Notification – Afinitor (everolimus)\nChange Control\n8/2014 Annual review. Added coverage for soft tissue sarcomas, Hodgkin\nlymphoma, and non-clear cell kidney cancer. Updated breast cancer to\ninclude tamoxifen as part of trial/failure and ‘advanced’ to type of\ncancer. Updated formatting, Background and References.\n9/2014 Administrative change – Tried/Failed exemption for State of New\nJersey removed.\n© 2025 UnitedHealthcare Services, Inc.\n12\n8/2015 Annual review. Updated criteria for breast cancer, Hodgkin lymphoma,\nlung neuroendocrine tumors and Waldenström’s macroglobulinemia /\nlymphoplasmacytic lymphoma. Increased authorization and\nreauthorization from 5 months to 12 months for all indications. Updated\nbackground and references.\n7/2016 Annual review. Consolidated neuroendocrine tumor criteria. Minor\nrevision to Renal Cell Carcinoma. Added indications and criteria for\nOsteosarcoma and Thymoma/thymic carcinoma per NCCN guidelines.\nUpdated background and references.\n7/2017 Annual review. Updated background and added criteria for thyroid\ncarcinoma and the bone cancers, dedifferentiated chondrosarcoma,\nhigh-grade undifferentiated pleomorphic sarcoma (UPS) per NCCN\nguidelines. Updated references.\n5/2018 Annual review. Updated background, added criteria for meningioma,\ngastrointenstinal stromal tumors, endometrial carcinoma, thymic\nneuroendocrine tumors, and updated breast cancer criteria per NCCN\nguidelines. Added criteria for new indication of tuberous sclerosis\ncomplex associated partial-onset seizures. Updated references.\n5/2019 Annual review. Updated background. Removed criteria for bone cancer\n(no longer recommended per NCCN guidelines). Updated reference.\n5/2020 Annual review. Updated backgrou",
    "s. Updated references.\n5/2019 Annual review. Updated background. Removed criteria for bone cancer\n(no longer recommended per NCCN guidelines). Updated reference.\n5/2020 Annual review. Updated background. Updated coverage criteria for soft\ntissue sarcoma, thymomas and thymic carcinomas, and meningiomas\nper NCCN guidelines. Updated references.\n5/2021 Annual review. Addition of criteria for osteosarcoma and Histiocytic\nNeoplasms, and update to kidney cancer criteria according to NCCN\nguidelines. Updated references.\n5/2022 Annual review. Updated background. Updated osteosarcoma criteria per\nNCCN guidelines. Updated references.\n5/2023 Annual review. Updated background. Updated Neuroendocrine tumor\nand Hodgkin lymphoma criteria per NCCN guidelines. Added state\nmandate and oncology medications footnote. Updated references.\n5/2024 Updated background to reflect current NCCN guidance. Updated\ncriteria for neuroendocrine tumors, advanced renal cell\ncarcinoma/kidney cancer. Renamed and updated criteria for tuberous\nsclerosis complex-associated renal cell carcinoma. Renamed and\nupdated criteria for subependymal giant cell astrocytoma section.\nUpdated criteria for breast cancer, soft tissue sarcomas, thymomas and\nthymic carcinomas, meningiomas, bone cancer - osteosarcoma, and\nhistiocytic neoplasms. Separated and updated criteria for\ngastrointestingal stromal tumor (GIST) from soft tissue sarcoma.\nRemoved oncology medications footnote.\n5/2025 Annual review. Updatedd criteira for neuroendocrine tumors, breast\ncancer, Hodgkin lymphoma, thyroid cancer, and gastrointestinal stromal\ntumors per NCCN guidelines. Updated section on endometrial\ncarcinoma and renamed uterine neoplasms. Consolidated sections for\nmeningioma and subependymal giant cell astrocytoma (SEGA) and\nrenamed central nervous system cancer. Consolidated sections for\ntuberous sclerosis complex (TSC)-associated renal cell carcinoma and\nadvanced renal cell carcinoma and renamed kidney cancer.\n© 2025 UnitedHealthcare Service",
    "s system cancer. Consolidated sections for\ntuberous sclerosis complex (TSC)-associated renal cell carcinoma and\nadvanced renal cell carcinoma and renamed kidney cancer.\n© 2025 UnitedHealthcare Services, Inc.\n13"
  ]
}